Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.64 |
| ▸ | IGF2R | P11717 | 4/20 | 0.57 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.46 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoribosyl Pyrophosphate SCHEMBL187952 | 1.00 | FBP1 (0.64) | FBP1IGF2RAMDHD2P2RY14B4GALT1 | |
| Phosphoribosyl Pyrophosphate SCHEMBL28174133 | 1.00 | FBP1 (0.64) | FBP1IGF2RAMDHD2P2RY14B4GALT1 | |
| Phosphoribosyl Pyrophosphate SCHEMBL28209513 | 1.00 | FBP1 (0.64) | FBP1IGF2RAMDHD2P2RY14B4GALT1 | |
| Phosphoribosyl Pyrophosphate SCHEMBL16018854 | 1.00 | FBP1 (0.64) | FBP1IGF2RAMDHD2P2RY14B4GALT1 | |
| Phosphoribosyl Pyrophosphate SCHEMBL30360449 | 0.98 | FBP1 (0.62) | FBP1IGF2RAMDHD2P2RY14B4GALT1 | |
| SCHEMBL1332683 | 0.87 | FBP1 (0.72) | FBP1IGF2RAMDHD2P2RY2 | |
| SCHEMBL1702604 | 0.87 | FBP1 (0.72) | FBP1IGF2RAMDHD2P2RY2 | |
| SCHEMBL3504366 | 0.86 | FBP1 (0.66) | FBP1IGF2RAMDHD2P2RY14B4GALT1 | |
| SCHEMBL18710785 | 0.85 | FBP1 (0.70) | FBP1IGF2RAMDHD2P2RY14B4GALT1 | |
| SCHEMBL8847405 | 0.85 | FBP1 (0.70) | FBP1IGF2RAMDHD2P2RY14B4GALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111184133-A | Pet health product and preparation method thereof | 张琦 | 2020-05-22 | — | — | CN | claimed |
| US-9644226-B2 | Method for producing vectors containing a gene coding for an enzyme having reduced or deactivated feedback inhibition and the use thereof for producing amino acids and nucleotides | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2017-05-09 | — | — | US | claimed |
| US-20150284760-A1 | METHOD FOR PRODUCING VECTORS CONTAINING A GENE CODING FOR AN ENZYME HAVING REDUCED OR DEACTIVATED FEEDBACK INHIBITION AND THE USE THEREOF FOR PRODUCING AMINO ACIDS AND NUCLEOTIDES | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2015-10-08 | — | — | US | claimed |
| WO-2015069860-A1 | BIOLOGICAL PRODUCTION OF NAD PRECURSORS AND ANALOGS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | WO | claimed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| EP-0205586-B1 | COMPOSITION COMPRISING UDPG AND OTHER ANTI-TUMOR DRUGS FOR TREATMENT OF TUMORS | MEMORIAL HOSPITAL CANCER (US) | 1994-06-22 | — | — | EP | claimed |
| EP-0406436-A1 | PROCESS FOR PREPARING 5'-INOSINIC ACID | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-01-09 | — | — | EP | claimed |
| WO-1986003678-A1 | COMPOSITION AND METHOD FOR TREATMENT OF TUMORS WITH UDPG | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) | 1986-07-03 | — | — | WO | claimed |
| CN-122075713-A | Deaminase and use of transaminase in the treatment of polyglutamine diseases | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4720100-A1 | MODIFIED VECTORS | CSL Behring LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| CN-120137864-A | Recombinant microorganism for producing L-histidine and application thereof | 北京绿色康成生物技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120137863-A | Recombinant microorganism and application thereof in fermentation production of L-histidine | 北京绿色康成生物技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-0458070-A1 | Cytidine analogue resistance gene DNA and its use | Takeda Chemical Industries, Ltd. (JP) | 1991-11-27 | — | — | EP | disclosed |
| EP-0406436-A1 | PROCESS FOR PREPARING 5'-INOSINIC ACID | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-01-09 | — | — | EP | disclosed |
| WO-1990014009-A1 | THERAPEUTIC APPLICATION OF AN ANTI-INVASION COMPOUND | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1990-11-29 | — | — | WO | disclosed |
| US-4885245-A | CONTACTING GENETICALLY ENGINEERED CORYNEFORM BACTERIUM WITH APPROPRIATE RAW MATERIALS | AJINOMOTO CO., INC. (JP) | 1989-12-05 | — | — | US | disclosed |
| WO-1986003678-A1 | COMPOSITION AND METHOD FOR TREATMENT OF TUMORS WITH UDPG | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) | 1986-07-03 | — | — | WO | disclosed |
| EP-0170257-A2 | Process for producing l-tryptophan | AJINOMOTO CO., INC. (JP) | 1986-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | FBP1 693/4885IGF2R 3320/4885AMDHD2 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.